Abstracts tagged "interstitial lung disease"

Abstract Number: 0882 • ACR Convergence 2025
Serum KL-6 as a Predictive Biomarker for Interstitial Lung Disease Progression and Mortality in Systemic Sclerosis: A Prospective Cohort Study
cristiana Sieiro¹, Jose Ordas Martínez², Sara Calleja Antolín², Juan Garcia Herrero², Javier De la Calle², Miriam Retuerto², Laura Sierra², Elena Bollo de Miguel² and Elvira Díez Álvarez², ¹Univrsity of Manchester, Manchester, United Kingdom, ²Complejo Asistencial Universitario de León, León, Spain
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in systemic sclerosis (SSc). Early detection and continuous monitoring of ILD are…
Abstract Number: 0154 • ACR Convergence 2025
Incidence and Prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-ILD) in the United States
Diana Martins¹, George Mu², Elaine Irving³, Roger A. Levy⁴, Nisha Bhatt⁵ and Keele E. Wurst⁶, ¹GSK, Epidemiology, Toronto, ON, Canada, ²GSK, Statistics, Collegeville, PA, ³GSK, Clinical, Stevenage, United Kingdom, ⁴GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁵GSK, Global Medical Affairs, Collegeville, PA, ⁶GSK, Immunology and Emerging Epidemiology, Durham, NC
Background/Purpose: Despite the high disease burden and reduced quality of life for patients with CTD-ILD, data on its incidence and prevalence – particularly by CTD…
Abstract Number: 2579 • ACR Convergence 2025
Mutant COPA Permits Aberrant NETosis and Exacerbates Autoimmune Lung Disease
Richard Moore¹, Lihong Huo¹, Colin Koziel¹, Barry Stripp², Tiphanie Vogel³, Daniel Wallace⁴ and Caroline Jefferies⁵, ¹Cedars-Sinai, Beverly Hills, CA, ²Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ³Baylor College of Medicine, Houston, TX, ⁴Cedars Sinai Medical Center, Studio City, CA, ⁵Cedars-Sinai Medical Center, Beverly Hills, CA
Background/Purpose: COPA syndrome is an autosomal dominant disease caused by missense mutations within the COPA gene. Typical onset begins during childhood with patients developing lung…
Abstract Number: 2229 • ACR Convergence 2025
National Multicenter study of Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease: effectiveness and progressive lung disease
Ana Serrano-Combarro¹, Belén Atienza-mateo², Jesús Loarce³, César Antonio Egües Dubuc⁴, Marta Pastor Mena⁵, Rafael B. Melero-González⁶, Sara Maria Rojas Herrera⁷, Carmen Carrasco-Cubero⁸, Carolina Perez Garcia⁹, Juan María Blanco-Madrigal¹⁰, Nuria Vegas Revenga¹¹, Deseada Palma-Sanchez¹², Andrea García-Valle¹³, Virginia Ruiz-Esquide¹⁴, Jose Ramón Lamua-Riazuelo¹⁵, Santos Castañeda¹⁶ and Ricardo Blanco¹⁷, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, ³Ramón y Cajal University Hospital, Madrid, Spain, ⁴Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁵Hospital de Jerez de la Frontera, Jerez de la Frontera, Spain, ⁶COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁷Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, ⁸Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁹Hospital del Mar, Barcelona, Spain, ¹⁰Rheumatology. Hospital Universitario Araba., Vitoria, Pais Vasco, Spain, ¹¹Galdakao- Usansolo University Hospital, Galdakao, Spain, ¹²Rheumatology. Hospital Rafael Méndez, Lorca, Murcia, Spain, ¹³Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ¹⁴Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹⁵Hospital Universitario del Henares, Madrid, Spain, ¹⁶Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁷Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Interstitial lung disease (ILD) in Rheumatoid Arthritis (RA) determines a worse prognosis with an increased mortality. Abatacept and rituximab may be the preferred therapies.…
Abstract Number: 1924 • ACR Convergence 2025
Real-World Treatment Patterns of Patients with Systemic Autoimmune Rheumatic Disease-associated Interstitial Lung Disease After Progression in The United States
Joseph Yang¹, Katy Sadowski¹, Akshay Kharat¹, Ann Chauffe¹ and Tejaswini Kulkarni², ¹Boehringer Ingelheim, Ridgefield, CT, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) are a group of autoimmune diseases that affect multiple organ systems, including the lungs. The development of interstitial lung…
Abstract Number: 1662 • ACR Convergence 2025
Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial
Anna-Maria Hoffmann-Vold¹, Shervin Assassi², Vincent Cottin³, Michael Kreuter⁴, Claudia Valenzuela⁵, Marlies S Wijsenbeek⁶, Hui Gu⁷, Ivana Ritter⁸, Susanne Stowasser⁸, Gerrit Weimann⁸ and Toby M Maher⁹, ¹Oslo University Hospital, Oslo, Norway, ²Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ³National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon ¹, UMR ⁷⁵⁴, ERN-LUNG, Lyon, France, Lyon, France, ⁴Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center and Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany, Heidelberg, Germany, ⁵Pulmonology Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain, Madrid, Spain, ⁶Center of Expertise for Interstitial Lung Diseases, Department of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁹Department of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA and Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK, Los Angeles
Background/Purpose: Nerandomilast is a preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. The Phase III FIBRONEER-ILD trial in patients with progressive pulmonary fibrosis…
Abstract Number: 1371 • ACR Convergence 2025
Effect of bDMARDs and tsDMARDS on diffuse interstitial lung disease associated with rheumatoid arthritis: systematic review and meta-analysis
Stéphane HILLIQUIN¹, Enrico VISMARA¹, Virginia BERLENGIERO² and Jérôme AVOUAC³, ¹Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France, PARIS, France, ²Rheumatoloy Department, Cochin Hospital, PARIS, France, ³Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA), associated with increased morbidity and mortality. The pulmonary safety of biologic (bDMARDs)…
Abstract Number: 1185 • ACR Convergence 2025
Pulmonary Arterial Hypertension in Adults with Still’s Disease: Another Pulmonary Manifestation Associated with HLA-DRB1*15
Stéphane Mitrovic¹, Athénaïs Boucly², Maryvonnick Carmagnat³, Laurent Savale², Xavier Jaïs², Jean-luc Taupin³, Estibaliz Lazaro⁴, Emilie Berthoux⁵, nicolas schleinitz⁶, Maria-Rosa Ghigna⁷, kedra joanna¹, Xavier Mariette⁸, Céline Roussin⁹, Pierre Antoine Juge¹⁰, Marc Humbert², Olivier Sitbon², David Montani² and Bruno Fautrel¹¹, ¹Pitié-Salpêtrière Hospital, Rheumatology Department, APHP, Sorbonne University,, Paris, France, ²Kremlin Bicêtre Hospital, Pulmonology Department, Paris Saclay University, APHP, Le Kremlin Bicêtre, France, ³Saint Louis Hospital, Immunology laboratory, APHP, Paris, France, ⁴Internal Medicine Department, CHU Bordeaux, Bordeaux, France, ⁵Saint Joseph Sain Luc Hospital, Internal Medicine Department, Lyon, Lyon, France, ⁶Aix Marseille university, AP-HM, Marseille, France, ⁷Marie Lannelongue Hospital, Anatomopathology department, Le Plessis-Robinson, France, ⁸Université Paris-Saclay, Le Kremlin Bicetre, France, ⁹Centre Hospitalier Ouest Réunion, Saint Paul, France, ¹⁰Hopital Bichat, APHP, Paris, France, ¹¹Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Inflammatory lung disease (ILD) in Still’s disease (SD) has recently been described. Pulmonary arterial hypertension (PAH), a rare subtype of pulmonary hypertension (PH), is…
Abstract Number: 0881 • ACR Convergence 2025
Circulating Monocytes with High Interferon Signature as Precursors to Osteopontin Expressing Lung Macrophages in Patients with Systemic Sclerosis and Progressive Interstitial Lung Disease
Shu-Ju Lin¹, Kimberly Taylor², Shen Yang³, Qinwei Chen⁴, Shehani Alexander¹, Ye Cao⁵, Takanori Sasaki⁵, Deepak Rao⁵, Nunzio Bottini⁶, Francesco Boin³ and Richard Ainsworth⁴, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²UC San Francisco, San Francisco, CA, ³Cedars-Sinai Medical Center, Beverly Hills, CA, ⁴Cedars Sinai Medical Center, Los Angeles, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Circulating monocytes with pro-inflammatory and pro-fibrotic phenotype have been implicated in SSc-ILD pathogenesis, but their potential trajectory to mature cell lineage macrophages driving organ-specific…
Abstract Number: 0085 • ACR Convergence 2025
Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease
Kensuke Suga¹, Amara Seng², Changfu Yao³, Tanyalak Parimon³, Youn Jung Choi², Justyna Fert-Bober⁴, Barry Stripp³, Jon Giles⁵, Peter Chen³ and Nunzio Bottini⁶, ¹Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, ²Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ³Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Cedars Sinai Medical Center, Los Angeles, CA, ⁶Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Interstitial lung disease (ILD) is one of the extra-articular manifestations of rheumatoid arthritis (RA) characterized by inflammation and/or fibrosis. Clinically relevant RA-ILD occurs in…
Abstract Number: 2500 • ACR Convergence 2025
Greater Economic Burden and Healthcare Resource Utilization in Patients with Systemic Sclerosis With Versus Without Interstitial Lung Disease: Results from a Systematic Literature Review
Emily Glowienka¹, Sarah Nickolls², Kevin Coady¹, Eesha Kodi³, Ian Steinfield¹, Florence Wilson³, Alicia N. Pepper³, Svetlana I. Nihtyanova⁴, Roger A. Levy⁵ and Daniel Moldaver⁶, ¹Precision AQ, Boston, MA, ²GSK, Research & Development, Stevenage, United Kingdom, ³Precision AQ, Vancouver, BC, Canada, ⁴GSK, Clinical Sciences, Research & Development, London, United Kingdom, ⁵GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁶GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada
Background/Purpose: SSc is a rare autoimmune connective tissue disorder; up to 64% of patients with SSc develop interstitial lung disease (ILD), which can result in…
Abstract Number: 2140 • ACR Convergence 2025
Identification of immune phenotypes in systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD) using high parameter flow cytometry
Haeja Kessler¹, Noel Gibson¹, Alyssa Sproles², Celine Lages¹, Paul Dascani³, Sherry Thornton⁴ and Grant Schulert⁴, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cytek Biosciences, Pittsburgh, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a unique subtype of juvenile idiopathic arthritis with life threatening complications including macrophage activation syndrome and chronic lung…
Abstract Number: 1904 • ACR Convergence 2025
Mapping CTD-ILD in a Spanish Cohort – the NIRRVANA Registry
Paula García-Escudero¹, Marta López-Maraver², Tetyana Lozinska-Lozinska², Carlos Maria Lizasoain Alustiza³, César Antonio Egües Dubuc⁴, Leire Suárez Zorrilla⁵, Mayra Nathali Rivas Zavaleta⁵, Elena Garmendia Sánchez⁵, Nuria Vegas Revenga⁶, Myriam Aburto Barreneche⁷, Guillén Sada Urmeneta⁸, Elena Abad Plou⁹, Maria Luz Garcia Vivar¹⁰, Inmaculada Paniagua Zudaire¹¹, Marta Inchausti Iguiñiz¹², Iñaki Salegi Etxebeste¹² and Jaime Calvo¹³, ¹Hospital Universitario Álava, Bilbao, Spain, ²Hospital Universitario Araba, Vitoria, Spain, ³Donostia University Hospital, San Sebastian, Pais Vasco, Spain, ⁴Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁵Hospital Universitario Cruces, Barakaldo, Spain, ⁶Galdakao- Usansolo University Hospital, Galdakao, Spain, ⁷Hospital Galdakao-Usansolo, Galdakao, Spain, ⁸Hospital Reina Sofía de Tudela, Tudela, Spain, ⁹Hospital Universitario Basurto, Bilbao, Spain, ¹⁰Basurto Hospital, Bilbao, Spain, ¹¹Hospital Universitario de Navarra, Pamplona, Spain, ¹²Hospital Universitario Donosti, Donosti, Spain, ¹³Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain
Background/Purpose: Interstitial lung disease (ILD) is a prevalent feature among patients suffering from connective tissue diseases (CTD), associated with considerable morbi-mortality. Nonetheless, this complication is…
Abstract Number: 1659 • ACR Convergence 2025
Prevalence and Progression of Multimorbidity in Rheumatoid Arthritis-Associated Interstitial Lung Disease
James Fagerland¹, Yangyuna Yang¹, Punyasha Roul², Tate Johnson¹, Scott Matson³, Grant Cannon⁴, Brian Sauer⁵, Jeffrey Curtis⁶, Joshua Baker⁷, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, OMAHA, NE, ²UNMC, Omaha, NE, ³University of Kansas, Kansas City, MO, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Multimorbidity, the presence of multiple chronic conditions, is common in RA, and the progression of multimorbidity in RA is associated with poor long-term outcomes.…
Abstract Number: 1361 • ACR Convergence 2025
Efficacy of Telitacicept in the treatment of Connective tissue disease-associated interstitial lung disease: A Potential therapeutic option
Mingfang Sun¹, Xue Chen², Ying Zhou², Yanlong Yang², Fei Xiao² and huanzi dai², ¹Daping Hospital, chongqing, China (People's Republic), ²Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China., Chongqing, China (People's Republic)
Background/Purpose: Connective tissue disease-associated interstitial lung disease(CTD-ILD) represents a significant cause of mortality among patients. Presently, research on treatment options for CTD-ILD is limited, with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].